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Validation of the Human Ozone Challenge Model
as a Tool for Assessing Anti-Inflammatory Drugs
in Early Development
Olaf Holz, Ruth Tal-Singer, Frank Kanniess, Kathy J. Simpson, Anthony Gibson,
Rupert S. J. Vessey, Stanislawa Janicki, Helgo Magnussen, Rudolf A. Jörres, and Kai Richter
Experimental ozone (O3) exposure of human sub-jects is known to elicit a reversible impairment in
lung function, as well as acute airway inflammation,
characterized primarily by submucosal infiltration of
neutrophils. The inflammatory response also includes
sputum neutrophilia and elevated concentrations of
inflammatory mediators in bronchoalveolar lavage and
induced sputum supernatants. This response can be
detected as early as 1 hour following exposure and may
persist for 18 to 24 hours following exposure.1-4
Owing to the fact that the response to ozone is well
characterized, reproducible, and reversible, it has been
used for testing the efficacy of anti-inflammatory com-
pounds in preclinical animal studies.5,6 Several
investigators have also used this model for testing
anti-inflammatory interventions in human subjects.
Pretreatment with the macrolide azithromycin had no
effect on ozone-induced neutrophilia,7 whereas treat-
ment with the cyclooxygenase inhibitor indomethacin
for 6 days inhibited the ozone-induced impairment in
pulmonary function in healthy volunteers.8 A 4-week
inhalation of the corticosteroid budesonide did not at-
tenuate ozone-induced airway inflammation in normal
subjects, but in subjects with mild asthma, budesonide
significantly reduced sputum neutrophilia and CXCL-
8 levels.9,10 It is not clear whether these conflicting ob-
servations were due to the differences in study popula-
tions, the duration of treatment, the dose of steroids, or
the concentration of ozone (270 vs 400 ppb).
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This study aimed to test the utility of the ozone challenge
model for profiling novel compounds designed to reduce air-
way inflammation. The authors used a randomized, double-
dummy, double-blind, placebo-controlled 3-period crossover
design alternating single orally inhaled doses of fluticasone
propionate (inhaled corticosteroids, 2 mg), oral prednisolone
(oral corticosteroids, 50 mg), or matched placebo. At a 2-week
interval, 18 healthy ozone responders (>10% increase in spu-
tum neutrophils) underwent a 3-hour ozone (250 ppb)/inter-
mittent exercise challenge starting 1 hour after drug treat-
ment. Airway inflammation was assessed at 2 hours (breath
condensate) and 3 hours (induced sputum) after ozone chal-
lenge. Compared to placebo, pretreatment with inhaled
corticosteroids or oral corticosteroids resulted in a significant
reduction (mean [95% confidence interval]) of sputum neu-
trophils by 62% (35%, 77%) and 64% (39%, 79%) and of
sputum supernatant myeloperoxidase by 55% (41%, 66%)
and 42% (25%, 56%), respectively. The authors conclude
that an optimized ozone challenge model (including ozone
responders and ensuring adequate drug levels during expo-
sure) may be useful for testing novel anti-inflammatory com-
pounds in early development.
Keywords: Ozone challenge; drug profiling; induced spu-
tum; exhaled breath condensate
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The objective of this study was to establish an opti-
mized ozone challenge model in healthy subjects and
to assess its utility for profiling anti-inflammatory com-
pounds in early stages of clinical development. To opti-
mize the model, we only included documented ozone
responders (>10% increase in sputum neutrophils)
and treated them with a single high dose of inhaled or
oral corticosteroids administered immediately before
the ozone/exercise challenge to ensure adequate drug
exposure. In addition, subjects were challenged with a
dose of ozone that is known to produce a moderate and
reproducible neutrophil influx into the airways (250
ppb with intermittent exercise over 3 hours).2
MATERIAL AND METHODS
Study Design
We performed a randomized, double-dummy, double-
blind, placebo-controlled, 3-period crossover study in-
vestigating inhaled doses of 2 mg of fluticasone propio-
nate (inhaled corticosteroids [ICS]) and matched oral
placebo, oral prednisolone (oral corticosteroids [OCS],
50 mg) and matched inhaled placebo, or both placebos
(Figure 1). At visit 1, a prestudy medical examination
was carried out, baseline exhaled breath condensate
(EBC) was collected, and the subjects’ ability to pro-
duce induced sputum was assessed. At visit 2, subjects
underwent a screening ozone challenge, including
EBC and sputum collection. Visit 6 consisted of a safety
medical examination. The study was approved by the
Ethics Committee of the Chamber of Physicians of the
State of Schleswig-Holstein, and all subjects gave their
written informed consent.
Study Population
Eighteen healthy, nonsmoking subjects (4 women/14
men, mean ± SD; age, 31.4 ± 8.4 years; mean forced ex-
piratory volume in 1 second [FEV1], 103.5 ± 13.3%
pred) able to produce sputum of sufficient quality,
known to be responsive to ozone (>10% absolute in-
crease in percent sputum neutrophils over baseline),
and free of respiratory tract infections for at least 3
weeks prior to tests were included (total screened: 35;
unable to produce sufficient amounts of induced spu-
tum: 6; insufficient response to ozone: 6). Subjects
were not hyperresponsive to methacholine, and those
with a positive skin prick test to a common allergen
were tested outside their allergen season.
Ozone Exposure
Each exposure consisted of 3 hours of intermittent ex-
ercise (15-minute rest, 15-minute exercise) using
equipment described previously.2 Ozone generated
from 100% oxygen was added to purified air and its
concentration monitored continuously. The analyzer
was calibrated by the Environmental Protection
Agency of the State of Hamburg, Germany.
Sputum Induction
We followed a previously described procedure,11 but
the sputum plugs from consecutive saline inhalations
were pooled and homogenized by mixing 1:4 with
Sputolysin (DTT, Calbiochem, Bad Soden, Germany),
followed by addition of 4 parts of phosphate-buffered
saline (PBS). Mean differential cell counts were ob-
tained from 2 observers counting 400 cells on coded
cytospins. Coded supernatants (stored at –80°C) were
analyzed by a contract laboratory using validated com-
mercial enzyme-linked immunosorbent assays
(ELISA). The limits of detection after dilution (to mini-
mize potential effects of DTT and to achieve sufficient
volume for measurements) were 400 pg/mL for IL-8
(CXCL-8, R&D Systems, Abingdon, UK), 40 µg/mL for
total protein (Dojindo Molecular Technologies, Inc,
Gaitherburg, Md), 62.5 pg/mL for IL-6 (R&D Systems),
25.6 pg/mL for TNF-α (Amersham Biosciences,
Buckinghamshire, UK), and 36 ng/mL for MPO
(Immundiagnostik, Bensheim, Germany).
Exhaled Breath Condensate
Exhaled breath condensate was collected during tidal
breathing with a nose clip (Ecoscreen, Viasys,
Hoechberg, Germany). After collection, the condensate
was quickly thawed, and aliquots were stored at –80°C.
The coded EBC samples were analyzed by a contract
laboratory without further processing.
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Figure 1. Study design. ICS, inhaled corticosteroids (fluticasone
propionate); OCS, oral corticosteroid (prednisolone); EBC, exhaled
breath condensate.
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Data Analysis
All statistical analyses were performed using SAS (Ver-
sion 8.2). Each endpoint was analyzed using separate
analysis of variance (ANOVA) models, adjusting for
terms due to treatment period and treatment (fixed ef-
fects), as well as subject (random effect). Data were log
transformed prior to analysis, where applicable, and
the adjusted means for each treatment calculated to-
gether with the appropriate mean and 95% confidence
intervals (CIs) for the comparisons of interest. Compar-
isons were made between fluticasone propionate (FP),
or predisolone, with placebo. Statistical significance
was declared if the 95% confidence interval for the dif-
ference did not contain 0 for untransformed data or 1
for log-transformed data.
RESULTS
Previous studies demonstrated that ozone challenge
can be performed safely in humans,2,3 provided that
lung function is monitored in regular intervals to avoid
marked deteriorations in lung function (decrease of
forced vital capacity and FEV1 by >50%), which are
known to occur in single ozone-sensitive subjects.4
None of the subjects included in the present study had
to discontinue the challenge due to a severe decline in
lung function, and those who experienced a fall in
FEV1 by more than 10% recovered within 2 hours.
Overall, the mean (± SD) change in FEV1 caused by the
ozone challenge (using the 3- to 7-hour minimum
postchallenge FEV1) was –3.62% ± 6.81% (10%; 90%
percentiles: –13.1%, 3.75%).
Effect of Ozone on Sputum Composition
Sputum cell differentials could be evaluated for all
subjects after all treatment periods. Cytospin quality, as
judged by 2 observers, did not result in the exclusion of
any sample. The overall geometric mean (95% CI)
squamous cell contamination was 5.5% (4.4%, 7.0%).
Compared to baseline (visit 1), the screening ozone ex-
posure (visit 2) resulted in a median (quartiles) in-
crease in total cell counts of 128% (46%, 210%). The
absolute number of neutrophils increased by 944%
(541%, 1348%), and the proportion of neutrophils in-
creased by 404% (174%, 634%), with a reciprocal cor-
responding decline in the proportion of macrophages
by –60% (–49%, –70%). The comparison between
screening visit 2 and placebo treatment revealed no sta-
tistically significant differences in sputum composi-
tion (Figure 2), suggesting that ozone-induced inflam-
mation was reproducible in these subjects.
Effect of Treatment on Sputum Composition
Sputum composition data following placebo and ste-
roid treatment are presented in Table I. Compared to
placebo, pretreatment with ICS resulted in a lower total
cell count and a lower number of neutrophils (Figure
2). Similar effects were observed after pretreatment
with OCS (Figure 2). Compared to placebo, we ob-
served a mean (95% CI) reduction in CXCL-8 of 49%
(21%, 67%) after ICS and 34% (0%, 56%) after OCS
treatment. Corresponding reductions in MPO concen-
trations were 55% (41%, 66%) and 42% (25%, 56%),
respectively. There was a significant relationship be-
tween the absolute number of neutrophils and the con-
centration of MPO in sputum supernatant (r = 0.74, P <
.001, both log transformed). Total protein levels were
not altered by ozone or by steroid treatment. Most of
the IL-6 and all TNF-α concentrations were below
assay detection limits.
Effects on Exhaled Breath Condensate
The mean (95% CI) volume of air exhaled through the
condenser was 126.8 (123.5, 129.0) L, resulting in 2.2
(2.1, 2.4) mL of EBC. No significant differences in the
concentrations of CXCL-8, nitrate, 8-isoprostane, or to-
tal protein were observed when comparing ICS, OCS,
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Figure 2. Neutrophils/mL sputum at baseline (visit 1), 3 hours after
ozone screening (visit 2), and 3 hours after ozone challenges follow-
ing a single-dose pretreatment with placebo, 2 mg fluticasone propio-
nate (inhaled corticosteroid [ICS]), or 50 mg prednisolone (oral
corticosteroid [OCS]). **P < .001 compared to placebo treatment.
 at LMU Muenchen on June 19, 2013jcp.sagepub.comDownloaded from 
and placebo. CXCL-1 and IL-6 were not detected in
EBC samples.
DISCUSSION
In this study, we demonstrated that single doses of in-
haled or oral corticosteroid were capable of signifi-
cantly attenuating ozone-induced airway inflamma-
tion in healthy subjects. We aimed to maximize the
likelihood of a positive outcome by including only sub-
jects who were known to be sensitive to ozone in terms
of neutrophilia and by ensuring adequate drug levels
during ozone exposure through an appropriate timing
schedule. Given these prerequisites, the challenge
model showed significant effects of both the inhaled
and the oral corticosteroids. The challenge as per-
formed in the present study therefore fulfills basic cri-
teria required for profiling novel anti-inflammatory
compounds, particularly their efficacy in reducing
acute airway neutrophilia. It suggests that taking the
marked steroid effects as a reference is a valid
approach.
Based on current knowledge, the airflow limitation
in chronic obstructive pulmonary disease (COPD) is as-
sociated with an abnormal neutrophilic inflammatory
response of the lungs to noxious particles or gases.12 Pa-
tients with COPD or smokers with chronic bronchitis
and excess mucus production show high numbers of
neutrophils in bronchoalveolar lavage or sputum.13 It is
thought that neutrophils promote the development
and the progression of the disease by the release of pro-
teases and the production of reactive oxygen species.12
Therefore, lowering the number of neutrophils within
the airways seems a reasonable strategy in the
pharmacotherapy of COPD and an indispensable pre-
requisite for potential future interventions that aim at
restoring the normal airway and lung architecture.
To test novel compounds for their ability to attenu-
ate neutrophil recruitment into the airways, human ex-
perimental model systems would be of significant
value. To ensure acceptability to participants and a
rapid turnaround time, acute inflammatory models are
preferable. There are several agents known to induce
acute neutrophilia, such as endotoxin and ozone.
Ozone was selected for this study, as the transient
neutrophilia caused by ozone is well documented to be
reproducible within subjects,2,14 it is completely re-
versible, and its bioreactivity is mainly based on its po-
tent oxidative capacity.15 It could therefore serve as a
model for oxidative stress experienced in asthma or
COPD exacerbations.
In line with previous observations,2 we found in-
creases in the number and percentage of neutrophils
that differed between individuals and were, at the
same time, reproducible within individuals. This was
shown by the correlation between the changes from
baseline (visit 1) to ozone screening (visit 2) and from
baseline to the ozone challenge following placebo
treatment (data not shown). This correlation was sig-
nificant, despite the fact that the study was not specifi-
cally designed to confirm this result. In particular, we
did not include a filtered air exposure and thus as-
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Table I Sputum Composition (N = 18)
Adjusted Means Mean Difference (95% CI)
Placebo ICS OCS ICS vs Placebo OCS vs Placebo
Macrophages, % 29.9 32.7 45.4 2.8 (–6.4, 12.0) 15.5 (6.2, 24.7)a
Neutrophils, % 61.5 53.2 42.9 –8.3 (–18.0, 1.4) –18.6 (–28.4, –8.9)a
Eosinophils, % 0.5 0.5 0.3 –0.04 (–0.5, 0.4) –0.23 (–0.7, 0.2)
Lymphocytes, % 2.3 2.2 1.4 –0.10 (–1.4, 1.2) –0.10 (–2.3, 0.4)
Adjusted Geometric Means Mean Ratio (95% CI)
TCC, 106/mL 6.33 3.01 3.28 0.48 (0.32, 0.72)a 0.52 (0.34, 0.78)a
Macrophages, 106/mL 1.74 0.86 1.37 0.49 (0.31, 0.78)a 0.79 (0.50, 1.25)
Neutrophils, 106/mL 3.80 1.49 1.34 0.39 (0.24, 0.65)a 0.35 (0.21, 0.58)a
Eosinophils, 106/mL 0.005 0.005 0.003 1.01 (0.22, 4.64) 0.50 (0.11, 2.30)
Lymphocytes, 106/mL 0.04 0.03 0.03 0.67 (0.16, 2.81) 0.59 (0.14, 2.52)
ICS, inhaled corticosteroid; OCS, oral corticosteroid; CI, confidence interval; TCC, total cell count per mL sputum.
a. Indicates that 95% CI does not contain 0 or 1 (log-transformed case), indicating significance at the 5% level.
 at LMU Muenchen on June 19, 2013jcp.sagepub.comDownloaded from 
sessed ozone responses solely by comparison with
baseline data.
Overall, there are few studies reporting the effects of
drugs on the inflammatory airway response to ozone in
human subjects, and the data on corticosteroids are
equivocal.9,10 Nightingale and coworkers9 enrolled
healthy subjects, treated them for 2 weeks with 800 µg
budesonide twice daily, exposed them to 400 ppb
ozone for 2 hours, and collected sputum 4 hours after
inhalation. In contrast, Vagaggini et al10 enrolled sub-
jects with mild asthma, who were treated with 400 µg
budesonide twice daily and exposed to 270 ppb ozone
for 2 hours. Sputum was sampled 6 hours after expo-
sure. Only the latter study (ie, the one performed in
subjects with asthma) showed a significant treatment
effect similar to our results obtained in healthy sub-
jects.10 The reason for the pronounced effect of steroids
in our study is most likely due to the fact that we ad-
ministered a high dose shortly before ozone exposures
and thereby ensured higher drug levels during the
challenge. Intersubject variability was also probably re-
duced because the study included only volunteers who
were proven to respond to ozone in terms of airway
neutrophilia. Another factor contributing to the posi-
tive outcome was likely the avoidance of the high level
of ozone, as used by Nightingale et al (400 ppb). This
represents a strong stimulus, which caused a marked
neutrophil influx into the airways (all subjects show-
ing >75%). In planning the study, we considered this
profound stimulus to be less amenable to blockade by
therapeutic intervention. Finally, the sampling time of
sputum and EBC was chosen earlier compared to the
previous studies, although we do not know in detail
whether this had a significant effect on the study out-
come. Bronchoalveolar lavage data indicate a peak of
inflammation about 6 hours after exposure.8 On the
other hand, significant and well-reproducible sputum
neutrophilia has been observed as early as 1 hour after
the end of exposure.2
Corticosteroids are known to attenuate inflamma-
tory processes by binding to steroid receptors and in-
teracting with promoters of genes involved in cell acti-
vation.16 Our study was designed to establish a positive
control for potential future studies with experimental
drugs. We therefore aimed to maximize the potential
for airway protection by a single dose of the drug, with-
out the necessity to reach hard-to-control steady-state
conditions. Thus, we used the highest single doses of
potent inhaled and oral steroids that had been shown
to be safe and well tolerated. Maximum plasma con-
centrations of prednisolone following 50 mg dosing are
reached within 1 hour.17,18 With a half-life of 4 hours,
we expected to cover the duration of the ozone expo-
sure adequately. Similar considerations hold for
fluticasone. We would like to point out that our study
did not intend to suggest such high-dose regimens as a
potential long-term treatment of neutrophilia either in
environmental ozone exposures or in patients with
airway neutrophilia.
As we aimed to study anti-inflammatory effects,
ozone responders were defined on the basis of a more
than a 10% increase in sputum neutrophils. Ozone ex-
posures are known to exert effects on lung function,
too. We observed only small effects on FEV1, without
significant differences between treatments, with mean
changes (preozone to postozone) being –1.4% at visit 2,
–4.2% after placebo, –5.0% after ICS, and –3.9% after
OCS. It is known that both lung function and
neutrophil responses to ozone are reproducible within
subjects2,14 but are independent of each other.2,4 Thus,
the observation of a marked steroid effect on airway
neutrophilia, without a concomitant effect on lung
function, is compatible with previous findings.
In the present study, airway inflammation was as-
sessed primarily via sputum composition, which is
known to be affected by ozone inhalation. To broaden
the range of potentially sensitive variables that can be
measured noninvasively, we also incorporated EBC
sampling and analysis. This required integration of this
method into the schedule of a clinical trial involving
the collection and intermittent storage of samples prior
to the analysis in specialized laboratories. Exhaled
breath condensate samples were repeatedly sent every
4 to 6 weeks during the trial duration of approximately
6 months, instead of just 1 shipment for sputum
supernatants. We therefore have to consider potential
effects of storage on the detection of some of the
compounds of EBC.
In conclusion, based on the present findings, we
propose an ozone challenge model for the induction of
acute neutrophilic airway inflammation that is amena-
ble to short-term therapeutic intervention. The compo-
nents of the model are a moderate ozone exposure,
healthy subjects with a documented response to ozone
in terms of airway neutrophilia, sputum induction 3
hours after exposure, and interventions by single high
doses of an inhaled or oral corticosteroid shortly before
exposures. Using this approach, fluticasone and
prednisolone significantly attenuated the neutrophil
influx into the upper airways. The design as described
in the present study might therefore be suitable for test-
ing novel anti-inflammatory compounds that are tar-
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geted to reduce airway neutrophilia, and the steroid ef-
fect might be used as a reference for establishing both a
scale of responses and comparability between studies.
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support.
REFERENCES
1. Aris RM, Christian D, Hearne PQ, Kerr K, Finkbeiner WE, Balmes
JR. Ozone-induced airway inflammation in human subjects as deter-
mined by airway lavage and biopsy. Am Rev Respir Dis.
1993;148:1363-1372.
2. Holz O, Jörres RA, Timm P, et al. Ozone-induced airway inflamma-
tory changes differ between individuals and are reproducible. Am J
Respir Crit Care Med. 1999;159:776-784.
3. Jörres RA, Holz O, Zachgo W, et al. The effect of repeated ozone ex-
posures on inflammatory markers in bronchoalveolar lavage fluid
and mucosal biopsies. Am J Respir Crit Care Med. 2000;161:1855-
1861.
4. Balmes JR, Chen LL, Scannell C, et al. Ozone-induced decrements
in FEV1 and FVC do not correlate with measures of inflammation.
Am J Respir Crit Care Med. 1996;153:904-909.
5. Hotchkiss JA, Hilaski R, Cho H, et al. Fluticasone propionate at-
tenuates ozone-induced rhinitis and mucous cell metaplasia in rat
nasal airway epithelium. Am J Respir Cell Mol Biol. 1998;18:91-99.
6. Giri SN, Benson J, Siegel DM, Rice SA, Schiedt M. Effects of pre-
treatment with anti-inflammatory drugs on ozone-induced lung dam-
age in rats. Proc Soc Exp Biol Med. 1975;150:810-814.
7. Criqui GI, Solomon C, Welch BS, Ferrando RE, Boushey HA,
Balmes JR. Effects of azithromycin on ozone-induced airway
neutrophilia and cytokine release. Eur Respir J. 2000;15:856-862.
8. Schelegle ES, Siefkin AD, McDonald RJ. Time course of ozone-
induced neutrophilia in normal humans. Am Rev Respir Dis.
1991;143:1353-1358.
9. Nightingale JA, Rogers DF, Fan CK, Barnes PJ. No effect of inhaled
budesonide on the response to inhaled ozone in normal subjects. Am
J Respir Crit Care Med. 2000;161:479-486.
10. Vagaggini B, Taccola M, Conti I, et al. Budesonide reduces
neutrophilic but not functional airway response to ozone in mild
asthmatics. Am J Respir Crit Care Med. 2001;164:2172-2176.
11. Holz O, Jörres RA, Koschyk S, Speckin P, Welker L, Magnussen H.
Changes in sputum composition during sputum induction in healthy
and asthmatic subjects. Clin Exp Allergy. 1998;28:284-292.
12. Global Initiative for the Chronic Obstructive Lung Disease: Global
Strategy for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease. NHLBI/WHO workshop report.
2001. NIH Pub. No. 2701.
13. Keatings VM, Barnes PJ. Granulocyte activation markers in in-
duced sputum: comparison between chronic obstructive pulmonary
disease, asthma, and normal subjects. Am J Respir Crit Care Med.
1997;155:449-453.
14. McDonnell WF III, Horstman DH, Abdul-Salaam S, House DE.
Reproducibility of individual responses to ozone exposure. Am Rev
Respir Dis. 1985;131:36-40.
15. Bascom R, Bromberg PA, Costa DL, et al. State of the art: health
effects of outdoor air pollution. Am J Respir Crit Care Med. 1996;
153:3-50.
16. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecu-
lar mechanisms. Clin Sci. 1998;94:557-572.
17. Greos LS, Vichyanond P, Bloedow DC, et al. Methylprednisolone
achieves greater concentrations in the lung than prednisolone: a
pharmacokinetic analysis. Am Rev Respir Dis. 1991;144:586-592.
18. Rohatagi S, Barth J, Mollmann H, et al. Pharmacokinetics of
methylprednisolone and prednisolone after single and multiple oral
administration. J Clin Pharmacol. 1997;37:916-925.
DRUG DEVELOPMENT 503
VALIDATION OF THE HUMAN OZONE CHALLENGE MODEL
 at LMU Muenchen on June 19, 2013jcp.sagepub.comDownloaded from 
